Outcomes of the Victo™ adjustable artificial urinary sphincter in the treatment of male incontinence

Objectives To report the clinical outcomes of the Victo™ (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery. Patients and Methods This study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively evaluated at baseline, and at 3 and 12 months after device activation, and thereafter annually. The 24‐h pad‐weight test (24hPWT) was used to assess severity of UI, while the Patient Global Impression of Improvement (PGI‐I) and patient satisfaction according to a Likert scale were used to measure patient‐reported outcomes. Results A total of 96 patients with a median (interquartile range [IQR]) age of 68 (65–72) years were included in the final analysis. The median (IQR) follow‐up was 3 (1–4) years. In all, 10 patients completed the 5‐year follow‐up. After the treatment, we observed a significant reduction in 24hPWT by the median of 83% (P